Ignite Creation Date:
2024-05-06 @ 5:45 PM
Last Modification Date:
2024-10-26 @ 2:34 PM
Study NCT ID:
NCT05411380
Status:
RECRUITING
Last Update Posted:
2022-11-04
First Post:
2022-06-05
Brief Title:
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive HER2-negative Breast Cancer After CDK46 Inhibitor
Sponsor:
Organization:
Sun Yat-sen University